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Review
Assessments of the import of an association 
observed between an environmental chemical 
exposure and child neurodevelopment often 
focus solely on the magnitude of the effect 
size and its associated p-value (i.e., whether it 
is < 0.05). Effect size is expressed in various 
forms, as the difference between the mean 
scores of exposed and unexposed groups, the 
change in score per unit change in an expo-
sure biomarker, or the change in risk (relative 
risk, odds ratio) associated with a particular 
value of the biomarker. Among the reasons 
cited to dismiss an effect size is that it is clini-
cally unimportant (e.g., Kaufman 2001). This 
perspective fails to place the effect estimate in 
a public health context, however. Estimating 
the population burden attributable to a fac-
tor requires a metric that reflects not only the 
magnitude of the risk associated with the fac-
tor but also the frequency with which the fac-
tor occurs in the population (Steenland and 
Armstrong 2006), a concept embodied in the 
environmentally attributable fraction model 
(Institute of Medicine 1981). Although a fac-
tor associated with a large impact would be a 
significant burden to a patient, it might not 
be a major contributor to population burden 
if it occurs rarely. Conversely, a factor asso-
ciated with a modest but frequently occur-
ring impact could contribute substantially to 
population burden.
The objective of this review was to describe 
a population-oriented approach to estimating 
risk factor burden as an alternative to the usual 
disease-oriented approach. This approach was 
then used to compare the population burdens 
associated with major medical, social, and 
chemical risks to child development.
Methods
Several choices were required to apply the 
approach.
Risk factors. An effort was made to esti-
mate the contributions to children’s neuro-
development of a wide range of medical 
conditions, including neurodevelopmental 
disorders, postnatal events, socioeconomic 
and psychosocial risks. The goal was not to 
provide an exhaustive accounting of all con-
tributors, however, and the selection of risk 
factors was not based on a systematic review, 
but on the availability of data.
End point for comparison. In most stud-
ies, a battery of neurodevelopmental tests 
assessing many domains is administered. Full-
Scale IQ (FSIQ) score is the end point most 
consistently reported across studies, however, 
and provides the best opportunity to conduct 
a comparative analysis. Among the instru-
ments used to assess neurodevelopment in 
children, FSIQ tests tend to be the strongest 
psychometrically, and an extensive body of 
research demonstrates relationships between 
FSIQ and many important late outcomes 
(Neisser et al. 1996).
Evidence on which effect sizes are based. 
Given the typical heterogeneity of the effect 
sizes derived from individual epidemiologic 
studies, basing the calculation on the effect 
size from a single study, particularly one of the 
first reported (Ioannidis 2005), would be an 
  invitation to controversy. An effect estimate 
derived from a meta-analysis or pooled analy-
sis, conducted by subject matter experts apply-
ing a transparent protocol for study inclusion 
and weighting, reflects the weight of evidence 
available on a risk factor. Therefore, prefer-
ence was given to effect estimates based on a 
meta-analysis or pooled analysis that provided 
evidence supporting a statistically significant 
association between a risk factor and FSIQ. 
In some cases, when such an analysis was not 
available, a single study was used, preferably 
one that was population based and with a large 
sample size. However, this was done in recog-
nition that the effect size would likely differ, to 
an uncertain extent, if based on an analysis that 
integrated the findings of multiple studies.
Population to which to generalize find­
ings. A population of 25.5 million 0- to 
5-year-old children in the United States was 
assumed (Federal Interagency Forum on 
Child and Family Statistics 2011). 
Method used to estimate FSIQ loss. For 
a categorical risk factor (i.e., one that a child 
either has or does not), the published preva-
lence of the factor in 0- to 5-year-old children 
was multiplied by the difference between the 
FSIQ scores of children with and without 
the risk factor (i.e., the effect size) to esti-
mate the total FSIQ loss associated with it. 
If only an estimate of yearly incidence was 
available (e.g., the number of events per year 
among children 0–5 years of age), the inci-
dence was multiplied by five (the number 
of yearly intervals in a population of 0- to 
5-year-olds) to estimate the total number of 
children in the cohort who would be expected 
to have experienced the risk factor. When the 
  prevalence/incidence among 0- to 5-year-olds 
was not available, it was estimated based on 
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the prevalence/incidence for the closest age 
range for which it was available.
For risk factors represented by a continu-
ous distribution, the numbers of 0- to 5-year-
old children (or the age range closest to this) 
with values in specified intervals of the dis-
tribution were calculated (e.g., 25th–50th 
percentile; 90th–95th percentile). Based on 
the dose–effect relationship for the risk factor, 
slopes for the FSIQ loss per unit increase in 
the factor were calculated, either across the 
entire distribution or, in the case of a nonlin-
ear relationship, over specific intervals of the 
exposure distribution. Within each interval, 
the slope was multiplied, first, by the mid-
point value of the risk factor (or the distance 
between the midpoint value and the value 
below which no association has been found to 
exist between the risk factor and FSIQ) and, 
second, by the estimated number of children 
in the interval. The FSIQ losses of children 
within intervals were then summed to derive 
the total number of FSIQ points lost. (See 
Table 1 for an example.)
The level of precision in the calculations 
reported here should not be overinterpreted. 
They are intended to provide only rough esti-
mates of the FSIQ losses associated with dif-
ferent risk factors for purposes of comparison.
Results
Medical conditions. Congenital heart disease. 
Karsdorp et al. (2007) conducted a meta-anal-
ysis in which estimates were derived for the 
FSIQ deficits associated with different forms 
of congenital heart disease, the most common 
structural birth defect. The scores of children 
with a ventricular or atrial septal defect were 
not impaired, but the scores of children with 
more complex lesions—such as tetralogy of 
Fallot (TOF), d-transposition of the great 
arteries (d-TGA), and hypoplastic left heart 
syndrome (HLHS)—were, with mean deficits 
of 2.55, 2.10, and 12.3 points, respectively. 
The incidence of TOF is 4 in 10,000 (Child 
2004), or 10,200 cases in children 0–5 years 
of age in the United States. The incidence of 
d-TGA is 3 in 10,000 (Martins and Castela 
2008), or 7,650 cases, and the incidence of 
HLHS is 2 in 10,000 (Barron et al. 2009), or 
5,100 cases. Therefore, the estimated num-
bers of FSIQ points lost are 26,010 (TOF), 
16,065 (d-TGA), and 62,730 (HLHS), total-
ing 104,805 points.
Preterm birth. Approximately 12.3% of 
U.S. children are born preterm (gestational age 
< 37 weeks) (Hamilton et al. 2010). In a meta-
analysis of 15 studies (1,556 cases; 1,720 con-
trols), Bhutta et al. (2002) calculated a mean 
FSIQ deficit among cases of 10.85 points, 
producing a total loss of 34,031,025 FSIQ 
points. The severity of preterm birth likely 
influences the magnitude of the deficit, but 
separate estimates for specific intervals of ges-
tational age were not available. The estimate 
of 10.85 points is based on studies published 
between 1988 and 2001, and it is possible 
that the deficit among contemporary samples 
of children born preterm has been reduced by 
improvements in neonatal intensive care prac-
tices. In some cohorts born after 2000, FSIQ 
at age 5 years is approximately the expected 
mean of 100, even among infants born at 
28 weeks of gestation and with birth weights 
of approximately 1,000 g (Lind et al. 2011).
Type 1 diabetes. The prevalence of type 1 
diabetes in U.S. children is approximately 1 in 
500 (~ 51,000 children). In a meta-  analysis 
of 19 studies (1,393 cases; 751 controls), 
Gaudieri et al. (2008) estimated standardized 
effect sizes of –0.35 and –0.28 for two con-
structs, crystallized intelligence (i.e., ability to 
apply skills, knowledge, and experience) and 
fluid intelligence (i.e., ability to think logi-
cally to solve novel problems), respectively, 
in children with early-onset disease (diagnosis 
at < 7 years of age) compared with controls. 
The mean of these two, as a proxy for FSIQ, 
is –0.315, corresponding to 4.73 points. 
Among children with late-onset disease, the 
effect sizes for crystallized and fluid intelli-
gence were –0.20 and –0.14, respectively, or 
a mean effect size of –0.17, corresponding to 
2.55 points. If half of the cases are assumed 
to be early onset and half late onset, the total 
FSIQ loss is estimated to be 185,640 points.
Acute lymphocytic leukemia. The most 
common malignancy in children, acute 
lymphocytic leukemia, occurs with an 
annual incidence of 10 in 100,000, primar-
ily in 2- to 5-year-olds, resulting in a total of 
12,750 cases among children < 5 years of age 
in the United States. In a meta-analysis involv-
ing 28 studies of children treated with cra-
nial radiation, intrathecal chemotherapy, or 
both, the average weighted standardized effect 
size for FSIQ was –0.71, corresponding to 
10.65 points (Campbell et al. 2007). Therefore, 
the estimated FSIQ loss is 135,788 points.
Brain tumors. Brain tumors are the most 
common solid tumor diagnosis in children 
and the second leading cause of death by dis-
ease. The annual incidence is 2.35 in 100,000 
children (Mulhern and Butler 2004), repre-
senting 599 cases yearly among U.S. children. 
In a meta-analysis of 32 studies involving 
1,096 children, Robinson et al. (2010) 
reported a weighted standardized effect size 
of –0.83 for FSIQ, corresponding to a loss of 
12.45 points. Therefore, the total FSIQ loss 
is 37,288 points. Significant heterogeneity of 
the effect sizes across studies was noted, most 
likely reflecting cohort differences in tumor 
subtype (e.g., medulloblastoma vs. astro-
cytoma) or differences in treatment protocols. 
Because of data limitations, however, tumor-
specific estimates could not be made.
Duchenne muscular dystrophy. Duchenne 
muscular dystrophy is the most common form 
of muscular dystrophy, occurring in 2.9 in 
10,000 male births (therefore, approximately 
1.5 in 10,000 total births [Centers for Disease 
Control and Prevention (CDC) 2009a]. This 
corresponds to 3,825 cases in U.S. children 
0–5 years of age. In a meta-analysis of 32 stud-
ies, which included 1,231 patients, Cotton et al. 
(2005) estimated a mean FSIQ of 82, represent-
ing a deficit of 18 points. Therefore, the total 
FSIQ loss is estimated to be 68,850 points.
Neurodevelopmental disorders. Autism 
spectrum disorders. The prevalence of autism 
spectrum disorders (ASDs) in the United 
States is approximately 1 in 110 (CDC 
2009b), or 231,818 children in the 0- to 
5-year age range. Although a meta-analysis 
of FSIQ scores of children with ASDs could 
not be found, Charman et al. (2011) con-
ducted a population-based study in the United 
Kingdom that involved identifying each child 
in a population of 56,946 who had either a 
local diagnosis of an ASD or a “Statement of 
Educational Needs.” FSIQ was measured in 
the 156 children identified. The percentages of 
children in severity categories were as follows: 
7.4% severe/profound (FSIQ < 35, or a loss 
of 65 points); 8.4% moderate (FSIQ 35–49, 
or an average loss of 58 points); 39.4% mild 
(FSIQ 50–69, or an average loss of 41 points); 
and 16.6% below average (FSIQ 70–84, or 
an average loss of 23 points). Another 25.4% 
were in the average range (85–114). Half of 
these children (12.7%) were assumed to have 
Table 1. Estimated numbers of FSIQ points lost from lead exposure for children in different intervals of the 
blood lead distribution.
Range of the BLL distribution (µg/dL)
Midpoint BLL 
(µg/dL)  FSIQ lossa
No. of 
children
No. of FSIQ 
points lost
0 to 50th percentile (0–1.43) 0.72 0.37 12,750,000 4,717,500
50th to 75th percentile (1.43–2.10) 1.77 0.90 6,375,000 5,737,500
75th to 90th percentile (2.10–2.98) 2.54 1.30 3,825,000 4,972,500
90th to 95th percentile (2.98–3.80) 3.39 1.73 1,275,000 2,205,750
95th to 98th percentile (3.80–7.50) 5.65 2.88 765,000 2,203,200
> 98th percentile (> 7.50) 15 6.10 510,000 3,111,000
Abbreviation: BLL, blood lead level.
aThe FSIQ losses associated with blood lead intervals < 98th percentile were calculated by multiplying the midpoint 
BLL in an interval by –0.51 IQ points/µg/dL, the slope estimated for BLL < 10 µg/dL in the pooled analysis (Lanphear et al. 
2005). The midpoint BLL of children with a BLL > 98th percentile was assumed to be 15, and the FSIQ loss was assumed 
to be 6.10 points (5.1 points lost up to a BLL of 10 µg/dL and an additional 1 point, which is one-half of the FSIQ loss esti-
mated in the pooled analyses to be associated with an increase in BLL from 10 to 20 µg/dL).Neurodevelopmental burden of environmental chemicals
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FSIQ scores between 85 and 99, with an aver-
age loss of 8 points. If these figures are applied 
to U.S. children, the estimated total FSIQ loss 
is 7,109,899 points.
Bipolar disorder. Based on the num-
ber of office visits that identify pediat-
ric bipolar disorder as the reason (from the 
National Ambulatory Medical Care Survey 
of the National Center for Health Statistics, 
1999–2003), Moreno et al. (2007) estimated 
the prevalence to be 6.67%. The weighted 
standardized effect size for FSIQ based on 
10 studies included in a meta-analysis is 
–0.32, corresponding to a loss of 4.8 points 
(Joseph et al. 2008), producing an estimated 
total loss of 8,164,080 points.
Attention deficit hyperactivity disorder. 
Based on parent report (from the National 
Survey of Children’s Health, United States, 
2007), 7.2% of children 4–17 years of age 
have a current diagnosis of attention defi-
cit hyperactivity disorder (ADHD) (CDC 
2010a). In a meta-analysis that included 137 
comparisons of FSIQ among children with 
ADHD and controls (Frazier et al. 2004), the 
weighted standardized effect size was –0.61 or 
9.15 points, producing an estimated total loss 
of 16,799,400 points.
Postnatal events. Traumatic brain injury. 
The number of cases of traumatic brain injury 
(TBI) is estimated to be 475,000 annually 
among children 0–14 years of age, with the 
highest incidence among children 0–4 years 
of age (Langlois et al. 2005). An assumption 
that 40% of TBI events occur in children 
0–5 years of age results in an estimate of 
~ 950,000 cases in the United States. In a 
meta-analysis, Babikian and Asarnow (2009) 
provided estimates of the mean FSIQ defi-
cits associated with TBI of differing sever-
ity, defined by Glasgow Coma Scale score 
(mild: 13–15; moderate: 9–12; severe: 3–8). 
Because recovery does occur, mostly in the 
24 months after injury, the estimated FSIQ 
deficits present 24 months postinjury were 
used. The mean deficits associated with mild, 
moderate, and severe TBI were 4.47, 8.99, 
and 16.59 points, respectively. Narayan et al. 
(2002) reported that 80% of TBIs are mild, 
10% moderate, and 10% severe. Therefore, 
the FSIQ loss associated with mild TBI is 
3,397,200 points; moderate TBI, 854,050 
points; and severe TBI, 1,576,050. The total 
estimated loss is therefore 5,827,300 points.
Socioeconomic, nutritional, and psycho­
social risks. Nonorganic failure to thrive. 
Some children fail to grow at the expected rate 
because of child abuse, neglect, parental men-
tal disorder, and the like. Various criteria are 
used to identify cases, including weight below 
the 5th or 3rd percentile, a decrease of two 
major percentile lines on a growth chart, and 
< 80% expected weight. In a meta-analysis of 
studies in which cases were identified from 
primary care settings, Corbett and Drewett 
(2004) reported a difference of 4.2 points in 
the FSIQ scores of cases (n = 502) and con-
trols (n = 523). The various definitions used 
imply different prevalences, but if as many as 
5% of children are assumed to be cases, the 
total estimated loss is 5,355,000 points.
Iron deficiency. In the National Health and 
Nutrition Examination Survey (NHANES) 
1999–2000, the prevalence of iron deficiency, 
defined as an abnormal value on two or more 
indicators (serum ferritin, transferring satura-
tion, free erythrocyte protoporphyrin) was 7% 
in 1- to 2-year-olds and 5% in 3- to 5-year-
olds (CDC 2002). In a meta-analysis of four 
supplementation trials (Sachdev et al. 2005), 
the weighted standardized effect size was 0.41, 
corresponding to an increase of 6.15 points 
in the FSIQ scores of iron-deficient children 
who received supplementation. Interpreting 
this value as an estimate of the loss among chil-
dren who do not receive supplementation and 
assuming a prevalence of 6%, the estimated 
FSIQ loss in U.S. children from iron deficiency 
is 9,409,500 points.
Environmental chemical exposures. 
Methylmercury. Using NHANES 1999–2000 
data, McDowell et al. (2004) reported the dis-
tribution of hair mercury levels in U.S. women 
of childbearing age (16–49 years). Levels for 
the 10th, 25th, 50th, 75th, 90th, and 95th 
percentiles were 0.04, 0.09, 0.19, 0.42, 1.11, 
and 1.73 µg/g, respectively. Axelrad et al. 
(2007) conducted a dose–response analysis that 
integrated the results of three major epidemio-
logical studies (New Zealand, Faroe Islands, 
Seychelles Islands), identifying a regression 
coefficient of –0.18 child FSIQ points per 
microgram per gram increase in maternal hair 
during pregnancy. This coefficient was derived 
on the basis of maternal hair mercury levels 
considerably greater than those of U.S. women 
(means in the Seychelles Islands and Faroe 
Islands cohorts were 6.8 µg/g and 4.3 µg/g, 
respectively). To estimate FSIQ loss, it was 
assumed that the coefficient applies to hair 
mercury levels > 1.11 µg/g (90th percentile), 
approximately the value on which the meth-
ylmercury reference dose is based (Rice et al. 
2003). A concentration of 1.73 µg/g (95th 
percentile) was assumed to be the midpoint 
hair mercury level of the 10% of U.S. women 
with a level > 1.11 µg/g. The estimated total 
FSIQ loss is therefore 284,580 points.
Some studies have reported adverse neuro-
developmental outcomes at maternal hair levels 
lower than those represented in the analy  ses by 
Axelrad et al. (e.g., Oken et al. 2008). If the 
slope of –0.18 FSIQ points per microgram per 
gram is assumed to hold over the full range of 
maternal hair mercury levels in U.S. women, 
the total loss would be 1,875,017 points.
Recent studies, as well as reanalyses of 
older studies, suggest that neurotoxicity of 
methylmercury is underestimated if account 
is not taken of the fact that fish consumption 
also provides exposure to beneficial nutrients 
(Budtz-Jorgensen et al. 2007; Lynch et al. 
2011; Oken et al. 2008). Because this was not 
done in the analyses by Axelrad et al. (2007), 
the coefficient might underestimate the true 
slope and thus result in an underestimate of 
the total FSIQ loss.
Although NHANES data are nationally 
representative, concern has been expressed that 
the relatively small sample size (n = 1,726) 
resulted in inadequate sampling of subgroups 
at particular risk, such as the families of sub-
sistence and sport fishermen (Knobeloch et al. 
2007) and certain ethnic groups in which fish 
is a particularly prominent part of the diet 
(Hightower et al. 2006) and among whom 
awareness of fish advisories is low (Knobeloch 
et al. 2005). If consumers of a diet high in fish 
are indeed underrepresented in NHANES, the 
FSIQ loss calculated on the basis of the dis-
tribution of hair mercury levels in that survey 
would be an underestimate. When exposure 
of women of childbearing age is concerned, 
it is also important to consider whether the 
body burden for a chemical increases with age 
(e.g., polychlorinated biphenyls and, to a lesser 
extent, methylmercury). If burden is positively 
associated with age, risk will be overestimated 
unless age-specific natality rates are taken into 
account (Axelrad and Cohen 2011).
Organophosphate  pesticides.  In 
NHANES 1999–2004, the 5th, 10th, 25th, 
50th, 75th, 90th, and 95th percentiles of 
the distribution of total urinary dialkyl phos-
phate (DAP) metabolites in pregnant women 
were 7.3, 9.3, 27.0, 65.0, 151.7, 237.2, and 
483.5 nmol/L, respectively (CDC 2011b). 
A meta-analysis that provides the dose–effect 
relationship between total DAP metabolites 
and children’s FSIQ is not available, but 
Bouchard et al. (2011) and Engel et al. (2011) 
both reported on the association between total 
urinary DAP metabolites in pregnant women 
and childhood FSIQ. In the cohort studied 
by Engel et al. (2007), the median total uri-
nary DAP metabolite concentration was 82 
nmol/L (interquartile range of 35–195). In 
the cohort studied by Bouchard et al. (2011), 
the range was roughly 50–500 nmol/L. The 
ranges observed in these studies are therefore 
reasonable approximations of the upper half 
of the distribution of urinary DAP concen-
trations of U.S. pregnant women. Bouchard 
et al. (2011) reported that a 10-fold increase 
in total urinary DAP was associated with a loss 
of 5.6 FSIQ points [95% confidence interval 
(CI): –9.0, –2.2; n = 297], whereas Engel 
et al. (2011) reported that a 10-fold increase 
was associated with a loss of 1.39 points (95% 
CI: –4.5, 1.77; n = 140). Weighting the effect 
estimates by sample size produces an expected 
loss of 4.25 FSIQ points for a 10-fold increase Bellinger
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in urinary DAP over this range, or a slope 
of –0.01 point/nmol/L. The studies do not 
provide information about the dose–effect 
relationship < 50 nmol/L, so this slope was 
applied only to the 50% of U.S. children 
with DAP levels > 65.0 nmol/L (the median). 
The studies also do not provide information 
about the relationship > 500 nmol/L, so the 
FSIQ loss for the 5% of U.S. children with a 
level > 483.5 nmol/L was assumed to be 4.25 
points. Combining the slope and the distribu-
tion of total urinary DAP levels produces a 
total estimated loss of 16,899,488 points. If 
levels < 50th percentile are associated with 
FSIQ loss, the total would be greater.
Lead. In NHANES 2005–2006, the 
50th, 75th, 90th, 95th, and 98th percen-
tiles of the blood lead distribution for U.S. 
children 1–5 years of age were 1.43, 2.10, 
2.98, and 3.80 µg/dL, respectively (CDC 
2011a). The 98th percentile was not reported, 
but in NHANES 2003–2004, it was 
10.0 µg/dL (CDC 2009c). Based on the per-
centage declines observed between NHANES 
2003–3004 and 2005–2006 in the 90th and 
95th percentiles (23.6% and 25.5%, respec-
tively), I estimated that the 98th percentile 
in NHANES 2005–2006 was 7.5 µg/dL. 
Estimates of the dose–effect relationship relat-
ing blood lead level to FSIQ in children were 
taken from the pooled analysis of Lanphear 
et  al.  (2005).  This  analysis,  involving 
> 1,300 children who participated in seven 
international prospective studies, identified 
a supralinear relationship over the range of 
2.4–30 µg/dL. The best fits over narrower 
ranges were linear, however. An increase in 
blood lead level from 2.4 to 10 µg/dL was 
associated with a decrement of 3.9 FSIQ 
points (i.e., a slope of –0.51 points/µg/dL). 
This slope was also assumed to apply to blood 
lead levels between 0 and 2.4 µg/dL, as recent 
risk assessments have concluded that it is not 
possible to identify a blood lead level below 
which no adverse impact can be discerned 
[European Food Safety Authority 2010; 
Joint FAO/WHO (Food and Agriculture 
Organization/World Health Organization) 
Expert Committee on Food Additives 2010]. 
In the pooled analysis, an increase in blood 
lead from 10 to 20 µg/dL was associated with 
an additional decrement of 1.9 FSIQ points. 
A blood lead level of 15 µg/dL was assumed 
for the 2% of children with a blood lead level 
above the 98th percentile and an average 
loss of 6.1 points (5.1 points for the range of 
0–10 µg/dL plus one additional point for the 
increase > 10 µg/dL). For children with blood 
lead levels < 10 µg/dL, the midpoint blood 
lead level for each interval was multiplied by 
–0.51 and the product then multiplied by 
the number of children in the interval. For 
children with levels > 10 µg/dL, the assumed 
midpoint of 15 µg/dL was multiplied by 
6.1 points. The total estimated FSIQ loss is 
therefore 22,947,450 points (Table 1). An 
uncertainty analysis was conducted using the 
lower and upper bounds of the 95% CIs for 
the slopes estimated in the pooled analysis. 
Assuming the lower and upper bounds yields 
an estimated total FSIQ loss of 14,185,905 
and 31,277,154 points, respectively.
Discussion
Based on the estimated number of FSIQ 
points lost, the population burdens associ-
ated with environmental chemical exposures 
of children are surprisingly large—in some 
cases larger than those estimated for major 
medical conditions and events (Table 2). This 
is attributable not so much to the magnitude 
of the effect sizes associated with chemicals, 
but to the prevalence of exposures associated 
with adverse impacts. For example, in the case 
of lead, because of the absence of a thresh-
old, every child contributes at least a little 
to population morbidity, and the cumula-
tive impact is substantial, even if the lower 
bound of the CI for the effect size is used. 
Furthermore, most of the total morbidity is 
contributed by children with blood lead levels 
< 10 µg/dL rather than by children with levels 
> 10 µg/dL, the current CDC level of con-
cern (Table 1). This illustrates the principle, 
applied in evaluating the impart of radiation 
exposure, that “it is the total dose falling on 
the whole population which determines the 
burden of health effects” (Rose 1991), and 
that “a large number of people at a small risk 
may give rise to more cases of disease than the 
small number who are at a high risk” (Rose 
1985). This led Rose (1981) to argue in favor 
of supplementing individually based interven-
tions, which target those at high risk, with 
population-based interventions designed to 
shift the population distribution of a health 
index in the direction of lower risk.
Another illustration of the important dis-
tinction between individual and population 
risk is provided by the epidemiology of Down 
syndrome. As individuals, older women are at 
substantially greater risk than younger women 
of delivering a child with Down syndrome, 
as the relative risk associated with a maternal 
age > 44 years is approximately 50 compared 
with women < 30 years. The birth rate among 
younger women is so much higher, however, 
that 50% of children with Down syndrome 
are born to women < 30 years of age. Despite 
its large relative risk, maternal age has a modest 
attributable fraction, and much of the popu-
lation burden is contributed by women who, 
individually, are at low risk. Although a factor 
that increases the odds ratio of a serious disease 
by 10-fold is clearly important for an affected 
individual, if it only increases the number of 
cases from 0.1 in 1,000,000 to 1 in 1,000,000, 
its import for population health is modest.
The notion that individuals with values on 
a health index that are not sufficiently extreme 
to meet diagnostic criteria may contribute 
substantially to population burden has been 
widely discussed in the context of chronic 
disease epidemiology. Applying categorical 
disease labels to individuals is necessary for 
clinical management and resource allocation. 
However, for many diseases that are defined 
using cutoff values of continuously distrib-
uted measurements (e.g., hypertension, dia-
betes, depression), the important question, 
as Rose (1993) noted, is not whether an indi-
vidual “has” the disease but “how much of 
it” one has. Quoting Pickering, Rose (1993) 
lamented that “medicine in its present state 
can count up to two but not beyond,” tend-
ing to regard disease and health as nonover-
lapping states. Goldberg (2000) observed that 
in insisting on categorical diagnoses, “rather 
than carving nature at the joints, we appear to 
be merely drawing lines in the fog.”
The strategies used to estimate the popu-
lation health burden associated with chemi-
cals have generally reflected a disease-oriented 
approach rather than a population-oriented 
approach. It is frequently noted that a modest 
shift in the mean IQ score in a population will 
be accompanied by a substantial increase in 
the percentage of individuals with extremely 
low scores. For example, Needleman et al. 
(1982) showed that the median verbal IQ 
scores of children with high and low dentine 
lead levels differed by only 5 or 6 points, but 
scores < 80 were three times more frequent in 
the high-lead group. This difference is surely 
important, but the cumulative frequency 
  distributions of the two groups differed 
throughout the entire range and, in fact, never 
intersected. Focusing solely on the difference 
Table 2. Estimated FSIQ point losses associated 







Congenital heart disease 104,805
Preterm birth 34,031,025
Type 1 diabetes 185,640
Acute lymphocytic leukemia 135,788
Brain tumors 37,288
Duchenne muscular dystrophy 68,850
Neurodevelopmental disorders
ASDs  7,109,899
Pediatric bipolar disorder 8,164,080
ADHD 16,799,400
Postnatal traumatic brain injury 5,827,300
Socioeconomic, nutritional, psychosocial factors
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between the distributions in the extreme left 
tail fails to acknowledge that the differences 
over the rest of the range of verbal IQ scores 
are also germane to population burden.
A disease-oriented approach underlies the 
protocol used by the WHO to estimate the 
global burden of disease, in that it is only 
health states associated with an International 
Classification of Diseases (ICD) code that con-
tribute to burden (WHO 2009). Fewtrell 
et al. (2003) used this protocol to estimate 
the burden attributable to lead. With regard 
to neurodevelopment, it was only children 
whose FSIQ score would be expected to be 
reduced to ≤ 70 (ICD category: mild mental 
retardation) as a result of lead exposure who 
contributed to the burden estimate. That a 
substantial fraction of the overall FSIQ loss 
in the calculations reported in this review is 
contributed by children with blood lead levels 
at the lower end of the exposure distribution, 
among whom few would be expected to meet 
criteria for mild mental retardation, indicates 
that a disease-oriented approach likely under-
estimates the contribution of lead to neuro-
developmental morbidity.
The population approach advocated here 
is consistent with the strategy economists use 
to assign monetary value to changes in FSIQ, 
which does not focus solely on the extreme 
low tail of the distribution. In estimating the 
economic benefits of reducing children’s lead 
exposure, Grosse et al. (2002) estimated that 
each FSIQ point lost reduces future work 
productivity by 1.76–2.38%, regardless of 
an individual’s initial FSIQ, a monetary loss 
placed by Gould (2009) at $17,815 in dis-
counted lifetime earnings.
The important risk factors for FSIQ loss 
likely vary across cultural and regional set-
tings. Although the intellectual burden associ-
ated with undernutrition, infectious diseases, 
and parasitic diseases is far greater among 
children in developing than in developed 
countries (Walker et al. 2007), exposures to 
environmental chemicals are also greater. In 
2000, < 10% of children worldwide had a 
blood lead level > 20 µg/dL, but 99% of them 
lived in developing countries (Fewtrell et al. 
2003), where tragic episodes of mass fatalities 
continue to occur (CDC 2010b).
The approach described in this review can 
be used to carry out a range-finding analysis 
of newly identified exposures and to prioritize 
research needs. For example, concern has been 
raised about the neurodevelopmental effects 
of children’s exposures to bisphenol A (Braun 
and Hauser 2011), polybrominated diphenyl 
ethers (Herbstman et al. 2010), and phthalates 
(Engel et al. 2010), but meta-analyses of these 
exposures have not been published. Keeping 
in mind that the effect estimates reported in 
initial studies of a risk factor tend to be larger 
than those reported in later studies (Ioannidis 
2005), one can nevertheless estimate the total 
FSIQ loss using the limited data available to 
get a preliminary sense of how important an 
exposure might be on a population basis.
Finally, the approach can be helpful in 
evaluating the impact of interventions to 
reduce population exposures. Applying 
it to the blood lead level data collected in 
NHANES II (1976–1980) (Mahaffey et al. 
1982) yields an estimated FSIQ loss of 
119,990,842 points for that cohort of chil-
dren, suggesting that measures taken in recent 
decades to reduce blood lead levels of children 
have produced a substantial reduction in neu-
rodevelopmental morbidity. The approach 
could also be used to compare the anticipated 
benefits of alternative regulatory initiatives 
based on the expected impact of an initiative 
on a biomarker distribution.
Limitations
Use of FSIQ as the basis for calculations. FSIQ 
was chosen as the end point for comparing 
risk factors, but this might not be the outcome 
that captures the most important impact of 
a risk factor. For example, among children 
with a TBI, deficits in visual-perceptual func-
tion are more prominent than deficits in FSIQ 
(Babikian and Asarnow 2009), and verbal 
memory and executive function are typically 
more impaired than FSIQ in children with 
bipolar disorder (Joseph et al. 2008). Because 
FSIQ averages performance over multiple 
domains, it is a poor metric for expressing the 
impact of a risk factor that selectively impairs 
certain domains, as has been suggested for 
methylmercury (Grandjean et al. 2006). Some 
risk factors, such as environmental tobacco 
smoke, might have their greatest impact on 
a child’s risk of behavioral disorders such as 
ADHD (Froehlich et al. 2009; Lindberg et al. 
2010). Therefore, for other end points, the 
relative importance of risk factors might differ 
from what was observed for FSIQ.
In some studies, the FSIQ scores of chil-
dren with a risk factor were compared with 
the scores of children in the standardization 
sample of the test used, whereas in others it 
was compared with the scores of a control 
group. Each strategy has advantages. Use of a 
control group can provide better control for 
confounding when studying a risk factor that 
tends to occur more often in particular sub-
groups of children (e.g., sickle cell disease). 
However, if the control group differs from 
the exposed group on important predictors of 
neurodevelopment and if adjustment for such 
factors is inadequate, the effect size derived 
could over- or underestimate the true value, 
depending on the circumstances.
Data used to support the calculations. The 
calculations carried out for different risk factors 
varied in terms of the quantity of data available 
(i.e., the number of studies, the number 
of children contributing data), resulting in 
differences in the weight and strength of the 
evidence that a risk factor is causally related to 
children’s FSIQ. For some risk factors, such as 
fetal alcohol syndrome/alcohol-related neuro-
developmental disabilities and environ  mental 
tobacco smoke, a published meta-analysis 
could not be found.. For other risk factors, 
the available meta-analyses involved ecologic 
comparisons not suitable for calculating FSIQ 
loss. For fluorosis (Tang et al. 2008) and 
arsenicosis (Dong and Su 2009), for example, 
meta-analyses reported only the mean FSIQ 
deficits of children in areas with endemic 
disease   compared with control areas.
Although relying on a meta-analysis 
reduces the problems associated with selecting 
a single study as the basis for calculations, such 
an analysis might not be accurate if it included 
studies that suffer from biases. Here I relied 
on the subject-matter experts who conducted 
the analyses to select the data on which to 
base the effect estimates. In some analyses, the 
effect estimates reported showed significant 
heterogeneity. This might reflect the presence 
of effect modification by characteristics that 
varied across studies (Bellinger 2009) or to 
methodological factors such as differences in 
the amount of exposure measurement error, 
which usually biases estimation toward the 
null (Grandjean et al. 2004). It could also be 
attributable to the presence of residual con-
founding in some of the studies included. 
Historically, confounding has been of prime 
importance, and the focus of most contention, 
in studies of environmental chemical expo-
sures, because of the frequent regulatory and 
economic implications of the causal inferences 
drawn. Equivalent attention might not be paid 
to such issues in studies of other risk factors 
and, to the extent that confounders have not 
been identified and adjusted for in the individ-
ual studies, the overall effect estimates derived 
in meta-analyses might be inaccurate.
For iron deficiency, the results of interven-
tion trials provided the effect estimate. Even if 
studies suggest that supplementation improves 
cognitive outcomes, the effect size might under-
estimate the FSIQ loss if supplementation does 
not fully reverse the impact of iron deficiency. 
In a meta-analysis of Chinese studies, the FSIQ 
deficit of children living in iodine-deficient 
areas was 12.45 points compared with chil-
dren from iodine-sufficient areas (Qian et al. 
2005). Children from iodine-deficient areas in 
which women received iodine supplementation 
during pregnancy recovered only 8.7 points, 
however. Prospective observational studies that 
do not involve supplementation would provide 
purer estimates of the impact of nutrient defi-
ciencies, although ethical considerations might 
prevent such studies
For some risk factors (e.g., iron deficiency, 
methylmercury), the effect estimates were Bellinger
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derived from studies conducted on non-U.S. 
samples. Important regional differences in 
the distributions of potential effect modifiers 
could reduce the appropriateness of extrapo-
lating the effect estimates to U.S. children. For 
example, the impact of a micronutrient defi-
ciency might be greater among children with 
comorbid health conditions, and the effect 
estimate derived on the basis of such a sample 
would overestimate the impact of the defi-
ciency among children who lack the comor-
bidities. Also, the effect estimates derived in 
some meta-analyses (e.g., of methylmercury) 
were derived on the basis of exposures that dif-
fer substantially from those of U.S. children, 
potentially compromising their usefulness.
Conceptual issues. Some risk factors for 
which calculations were made are likely to lie 
on the same causal pathway as other risk fac-
tors. For example, because increased exposure 
to air pollutants has been associated with pre-
term birth, some portion of the burden cal-
culated for preterm birth might represent an 
indirect effect of such exposures (Llop et al. 
2010). In some cases, it might be possible 
to disentangle the contributions of different 
risk factors. For instance, Braun et al. (2006) 
estimated that one in five ADHD cases can 
be attributed to children with a blood lead 
level > 2 µg/dL. The WHO Global Burden 
of Disease methodology addresses this gen-
eral problem by establishing disease “enve-
lopes” (WHO 2009). For example, the total 
number of known deaths from hepatocellular 
carcinoma establishes an upper bound for the 
number of cases that can be attributed to its 
various causes (e.g., hepatitis B, hepatitis C, 
alcoholism, aflatoxin exposure). If the number 
of deaths attributed to all causes exceeds this 
total, double counting has likely occurred. 
Because FSIQ loss is not a reported disease, 
however, such bounding cannot be used to 
constrain the calculations.
Finally, it is likely that risk factors inter-
act with one another to influence FSIQ of 
children. For example, not only do children 
living in poverty tend to experience greater 
exposures to environmental chemicals than do 
children living in advantaged circumstances 
(Elliott et al. 2004), but increasing evidence 
also suggests that material hardship, increased 
stress, and lack of enrichment opportunities 
exacerbate chemical neurotoxicity (Weiss and 
Bellinger 2006). Because of limitations in the 
available data, the impact of such interactions 
could not be estimated.
Conclusion
Any effort to compare the neurodevelop-
mental burden associated with different risk 
factors is limited by the data available and 
the assumptions required. It was possible to 
estimate the total loss of FSIQ points in the 
population of 0- to 5-year-old U.S. children 
for a variety of risk factors, including three 
environmental chemicals: methylmercury, 
organophosphate pesticides, and lead. Despite 
the limitations of the approach, it appears 
that when population impact is considered, 
the contributions of chemicals to FSIQ loss in 
children are substantial, in some cases exceed-
ing those of other recognized risk factors for 
neurodevelopmental impairment in children. 
The primary reason for this is the relative 
ubiquity of exposure. As a community, we 
have not effectively communicated this point 
to risk assessors and other decision makers, 
despite the fact that a risk assessment that 
focuses solely on individual risk and fails to 
consider the problem in a public health con-
text is potentially misleading.
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